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Introduction: The association between history of coronary artery
bypass graft surgery (CABG) and dementia risk remains unclear.
Methods: We conducted a prospective cohort analysis using data
on 3155 elderly adults free from prevalent dementia from the US
population-based Cardiovascular Health Study (CHS) with adju-
dicated incident all-cause dementia, Alzheimer disease (AD), vas-
cular dementia (VaD), and mixed dementia.
Results: In the CHS, the hazard ratio (HR) for all-cause dementia
was 1.93 [95% confidence interval (CI), 1.36-2.74] for those with
CABG history compared with those with no CABG history after
adjustment for potential confounders. Similar HRs were observed
for AD (HR=1.71; 95% CI, 0.98-2.98), VaD (HR=1.42; 95%
CI, 0.56-3.65), and mixed dementia (HR=2.73; 95% CI, 1.55-
4.80). The same pattern of results was observed when these CHS
findings were pooled with a prior prospective study, the pooled
HRs were 1.96 (95% CI, 1.42-2.69) for all-cause dementia, 1.71
(95% CI, 1.04-2.79) for AD and 2.20 (95% CI, 0.78-6.19) for VaD.
Discussion: Our results suggest CABG history is associated with
long-term dementia risk. Further investigation is warranted to
examine the causal mechanisms which may explain this relationship
or whether the association reflects differences in coronary artery
disease severity.
Key Words: coronary artery bypass graft surgery, dementia,
Alzheimer disease, vascular dementia, mixed dementia
(Alzheimer Dis Assoc Disord 2017;31:120–127)
Vascular disease is an important established contributorto vascular and mixed dementia.1 However, the rela-
tionship with coronary artery disease (CAD) and associated
treatments, for example, coronary artery bypass graft sur-
gery (CABG) is less clear. CABG is increasingly performed
in older adults who are at risk of dementia.2 In a study of
326 adults aged 55 years and older, prevalence of dementia
was markedly increased 7.5 years after CABG and
amounted to 30.7% [95% confidence interval (CI), 23-40].3
However, it remains unclear whether any increased risk of
dementia associated with CABG is a consequence of the
procedure, CAD itself, the progression of underlying dis-
ease, or a combination of these factors.2 CABG may
increase dementia risk via mechanisms such as release of
microemboli, hypoperfusion limiting the washout of
microemboli and systemic inflammation, or decrease
dementia risk due to other mechanisms such as improved
cardiac output.4 Comparisons with alternative CAD treat-
ments such as percutaneous coronary intervention (PCI)
are therefore useful because they can shed light on the
impact of the procedure itself.2
Dementia-related outcomes seem unrelated to procedural
differences in CABG, such as off-pump versus on-pump CABG5
or normothermic versus hypothermic cardiopulmonary
bypass.6,7 A recent meta-analysis of 28 studies of cognition up to
12 months following CABG suggested that psychomotor speed
was reduced up to 2 weeks after surgery, though memory and
executive function were preserved.8 These initial deficits resolved
within 3 months and were stable or improved at 6 to 12
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months.8 These findings should be interpreted with caution due
to methodological problems such as practice effects and lack of a
control group in many studies. Prior prospective studies provide
a mixed pattern of results. A 5-year follow-up study did not find
a significant difference in incidence of cognitive decline in CABG
patients compared with controls without CAD.9 Another study
with a 6-year follow-up comparing those with on-pump CABG
to those with off-pump CABG, CAD with medical manage-
ment, and those without CAD suggested that CAD treatment
strategies were not associated with the degree of long-term
cognitive decline.10 In a male co-twin control study matched for
CABG within each pair, those who received CABG aged 60 to
73 improved in global cognitive function 1 to 2 years post-
operatively.11 No significant differences were observed in twins
who had CABG later in life.11 However, in another population-
based cohort study CABG was associated with global cognitive
decline >5 years postoperatively but not in the first 5 years after
surgery.12 This suggests that CABG may confer long-term
rather than short-term risk of cognitive decline, and by impli-
cation may increase the risk of dementia. We therefore con-
ducted a systematic review focusing on the long-term relation-
ship between CABG and all-cause dementia and its subtypes
(Supplemental Methods and Results, Supplemental Figure 1 for
search strategy, Supplemental Figure 2 for search results, Sup-
plemental Table 1 for characteristics of included studies and
Supplemental Table 2 for quality assessment, Supplemental
Digital Content 1, http://links.lww.com/WAD/A158). Four
studies investigated the association with all-cause demen-
tia,13–16 3 studies with Alzheimer disease (AD),14,15,17 and 2
studies with vascular dementia (VaD)14,18 (Table 1). Two of
the included studies were based on data from the Car-
diovascular Health Study (CHS): a risk index study where
CABG predicted all-cause dementia risk though specific
effect size estimates were not reported13 and a secondary
analysis indicating an increased risk of VaD in those with
CABG history compared with no CABG history though
adjusted only for age, race, and sex and excluding prevalent
mild cognitive impairment (MCI) cases18 (Table 1). Results
from the Cache County Study14 supported the association
between CABG history and increased VaD risk. Estimates
for all-cause dementia and AD were in the same direction
but statistically not significant.14 A case-control study based
on medical records15 did not find a significant association
between CABG and odds of all-cause dementia and AD.
Another medical records study investigated risk of all-cause
dementia in those with CABG compared with those receiv-
ing medical management for CAD or those with PCI and
found no significant associations.16 However, Lee et al17 also
compared CABG to PCI in a medical records study and
found a significantly increased risk of AD (Table 1).
Given the mixed pattern of results and the limited
number of studies emerging from our systematic review, we
analyzed the CHS data to investigate the relationship
between CABG history and all-cause dementia and key
dementia subtypes including AD, VaD, and mixed dementia.
METHODS
Data and Study Population
We used data from the CHS, a large prospective,
population-based study of older adults that recruited 5201
white and African American participants in 1989 to 1990
and an additional 687 African American participants in
1992 to 1993 from 4 communities in the United States.19 Of
these 5888 participants, 3608 participants with a magnetic
resonance imaging (MRI) scan and a Modified Mini-
Mental State Examination assessment in 1991 to 1994 were
included in the CHS Cognition Study. This ancillary study
was designed to identify participants with prevalent
dementia at the time of the MRI examination (baseline for
the current study) or incident dementia or MCI from the
time of the MRI examination to the end of follow-up in
1998 to 1999, death, or loss to follow-up.13,20,21 We
excluded participants with prevalent dementia at baseline
(n=227), insufficient data to determine dementia status
(n=6), or a missing history of CABG at baseline (n=17)
resulting in a sample of 3358 participants. We then
restricted our sample to those with full data on all potential
covariates to be included in our fully adjusted model, giving
us our final sample of 3155 participants. Institutional
review committees at each study site approved the study,
and all participants provided written informed consent.
Sensitivity analyses including genetic data were restricted to
those providing additional consent to use their DNA.
Dementia Assessment
All-cause dementia was ascertained in 1998 to 1999 by
an adjudication committee of neurologists and psychiatrists
with expertise in dementia based upon previous (mainly
the Modified Mini-Mental State Examination and the Tele-
phone Interview for Cognitive Status) and current cognitive
assessments (including tests of premorbid intelligence,
memory, language, visuoconstructional/visuospatial, execu-
tive and motor functions), neurological examination, medi-
cal records, questionnaires, and informant reports.20,22 MRI
scans were used to classify dementia cases into subtypes.20
Classification of all-cause dementia and key dementia sub-
types (AD, VaD, and mixed dementia) was based on the
Diagnostic and Statistical Manual of Mental Disorders,
edition 4 or the National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer Disease
Related Disorders Association, the State of California Alz-
heimer Disease Diagnostic and Treatment Centers and the
National Institute of Neurological Diseases and Stroke-
Association Internationale pour la Recherche et l’Enseigne-
ment en Neurosciences.20
Assessment of CABG and PCI
We defined history of CABG (yes/no) and PCI (yes/
no) at baseline as self-reported history at CHS entry or
documented incident CABG or PCI from medical records
from CHS entry to study baseline.
Covariates
We adjusted our analyses for covariates identified as
potential confounders: age (years), sex, ethnicity (white/
non-white), education status (did not finish high school;
finished high school/some college/vocational qualifications;
college/professional qualifications), hypertension (no
hypertension: systolic <140 and diastolic <90; treated
hypertension: taking hypertensive medication; untreated
hypertension—systolic Z140 or diastolic Z90, with no
hypertensive medication), diabetes (American Diabetes
Association guidelines: having plasma fasting glucose
Z7.0mmol/L or using oral hypoglycaemic agents or insu-
lin), clinical cardiovascular disease (CVD; defined as any of
the following: atrial fibrillation or pacemaker, history of
intermittent claudication, or peripheral vascular surgery,
history of congestive heart failure, history of stroke, tran-
sient ischemic attack, or carotid surgery, history of
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coronary angioplasty, history of angina, or use of nitro-
glycerin, history of myocardial infarction) or subclinical
CVD (any of the following: ankle-arm index r0.9mm Hg,
internal carotid wall thickness >80th percentile, common
carotid wall thickness >80th percentile, carotid stenosis
>25%, major electrocardiogram abnormalities, abnormal
ejection fraction on echocardiogram, abnormal wall motion
on echocardiogram, Rose Questionnaire positive for clau-
dication or angina),23 body mass index in kg/m2, depressive
symptoms (Z8 on the revised 10-item Center for Epi-
demiologic Studies Depression Scale),24 smoking (non-
smokers including former smokers, current smokers),
alcohol consumption [US National Institute on Alcohol
Abuse and Alcoholism guidelines for older adults: non-
drinkers including former drinkers, moderate drinkers (r7
drinks per week), heavy drinkers (>7 drinks per week)],
physical activity (number of blocks walked over 1 week)25
and apolipoprotein E status (yes/no; presence of 1 or 2 e4
alleles).
Statistical Analysis
Those with and without CABG history were compared
regarding their baseline characteristics using a Student t test
for normally distributed continuous variables, a Wilcoxon
rank-sum test for skewed continuous variables and a
Pearson w2 test for categorical variables. We used Cox
proportional hazards models to examine the associations
between history of CABG (predictor) and time to incident:
(i) all-cause dementia, (ii) AD, (iii) VaD, and (iv) mixed
dementia. Participants were considered at risk for dementia
from baseline and were censored at death, incident CABG
(in the comparison group only), or the end of follow-up.
All-cause dementia included cases with AD, VaD, mixed
dementia, other rarer dementia subtypes, and cases with an
TABLE 1. Results of Included Studies for the Association Between CABG and Incident Dementia
Study Dementia Diagnosis
CABG
Assessment Adjustment Effect Size 95% CI
All-cause dementia
Barnes
et al13
Adjudicated based on the
NINCDS-ADRDA and
SCADDTC criteria
Self-reported Age, baseline cognitive function, BMI,
APOE E4 alleles, MRI evidence of white
matter disease or enlarged ventricles,
internal carotid artery thickness,
difficulty dressing, alcohol consumption
Not reported* Not reported*
Hayden
et al14
Adjudicated based on the
DSM-III-R criteria
Self-reported
or
informant-
reported
Age, sex, education, APOE E4 alleles,
hypertension, cholesterol, diabetes,
obesity, stroke, myocardial infarction
HR=2.09 0.91-4.41
Knopman
et al15
Adjudicated based on
medical records
according to DSM-IV
criteria
Medical
records
Education; dementia patients matched to
dementia-free controls by age and sex
OR=0.85 0.48-1.48
Mutch
et al16
Medical records, ICD-9-
CM diagnoses
Medical
records
Age, sex, income, diabetes, hypertension CABG vs. MM:
HR=0.90
CABG vs. PCI:
HR=1.35w
CABG vs. MM:
0.72-1.12
CABG vs. PCI:
0.89-2.04w
Alzheimer disease
Hayden
et al14
Adjudicated based on the
NINCDS-ADRDA
criteria
Self-reported
or
informant-
reported
Age, sex, education, APOE E4 alleles,
hypertension, cholesterol, diabetes,
obesity, stroke, myocardial infarction
HR=1.69 0.53-4.43
Knopman
et al15
Adjudicated based on
medical records
according to DSM-IV
criteria
Medical
records
Education; dementia patients matched to
dementia-free controls by age and sex
OR=0.76 0.37-1.55
Lee et al17 Medical records, ICD-9
diagnoses
Medical
records
Age, number of surgeries, number of
comorbidities, length of stay for index
hospitalization
CABG vs. PCI:
HR=1.71
CABG vs. PCI:
1.02-2.87
Vascular dementia
Kuller
et al18
Adjudicated based on the
SCADDTC criteria
Self-reported Age, race, sex HR=2.6 1.7-4.1
Hayden
et al14
Adjudicated based on the
NINDS-AIREN criteria
Self-reported
or
informant-
reported
Age, sex, education, APOE E4 alleles,
hypertension, cholesterol, diabetes,
obesity, stroke, myocardial infarction
HR=4.17 1.07-14.81
*Effect size not reported, though reported to be a significant predictor in the regression model with an OR r2.12 (log OR converted to OR for
comparability of results).
wComparison group reversed for comparability of results; PCI versus CABG: HR=0.74 (0.49-1.12).
APOE indicates apolipoprotein E; BMI, body mass index; CABG, coronary artery bypass graft surgery; CI, confidence interval; DSM-III-R, Diagnostic
and Statistical Manual of Mental Disorders, 3rd edition, Revised; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; HR, hazard
ratio; ICD-9; International Classification of Diseases, 9th revision; ICD-9-CM, International Classification of Diseases, 9th revision, Clinical Modification;
MM, medical management; MRI, magnetic resonance imaging; NINCDS-ADRDA, National Institute of Neurological And Communicative Diseases and
Stroke-Alzheimer’s Disease and Related Disorders Association; OR; odds ratio; PCI, percutaneous coronary intervention; SCADDTC, State of California
Alzheimer’s Disease Diagnostic and Treatment Centers.
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unspecified dementia subtype due to insufficient informa-
tion. Participants with prevalent MCI were included and
classified as not having dementia. In analyses of incident
AD, participants were censored for non-AD dementia, with
a similar approach used for VaD and mixed dementia. In
basic adjusted models, we controlled for age, sex, ethnicity,
and education. In fully adjusted models, we also included
baseline hypertension, diabetes, and clinical or subclinical
CVD. The proportional hazards assumption was assessed
by examining the Schoenfeld residuals.26
In sensitivity analyses, we fitted the same model including
additional adjustments for body mass index, depressive
symptoms, smoking, alcohol consumption, physical activity,
and apolipoprotein E. We also restricted the sample to those
with prevalent CVD or CAD (defined as prevalent myocardial
infarction or angina pectoris) and excluded participants who
developed dementia within 1 year of baseline to address the
possibility that any observed association may result from these
“early converters” as previously described.27
In secondary analyses we compared those with history
of CABG to those with history of PCI. We also conducted
random-effects meta-analyses to pool the CHS estimates with
compatible data from studies identified in the systematic
review. Heterogeneity was investigated using the w2 test and
the I2 statistic.28 Two-sided P<0.05 were considered stat-
istically significant. Data analyses were performed using Stata
SE version 13 (Stata Corp., College Station, TX).
RESULTS
Baseline characteristics of the study population are
presented in Table 2. Participants were followed-up for a
median of 6.0 years (interquartile range, 4.7 to 6.5). In the
comparison group (no history of CABG) 116 participants
were censored at the occurrence of incident CABG. Results
from the basic and fully adjusted models did not differ
substantially (Table 3). History of CABG almost doubled
the risk of developing all-cause dementia compared with no
history of CABG [fully adjusted hazard ratio (HR)=1.93;
95% CI, 1.36-2.74]. In terms of dementia subtypes, history
of CABG almost tripled the risk of developing mixed
dementia compared with no history of CABG (fully
adjusted HR=2.73; 95% CI, 1.55-4.80). The pattern of
associations was similar for AD and VaD but not statisti-
cally significant. Kaplan-Meier curves for unadjusted rates
of incident all-cause dementia and its subtypes indicate that
the survival curves begin to diverge after 1 year from
baseline and the 95% CIs separate after around 3 years for
all-cause dementia and 5 years for mixed dementia (Fig. 1).
Sensitivity analyses with additional adjustment did not
change the overall pattern of associations (Supplemental
Table 3, Supplemental Digital Content 1, http://links.lww.
com/WAD/A158). Similarly, restricting the sample to those
with CVD or CAD or excluding participants who devel-
oped all-cause dementia and its subtypes within 1 year of
baseline did not alter the pattern of results (Supplemental
Table 3, Supplemental Digital Content 1, http://links.lww.
com/WAD/A158). Comparisons between those with a
history of CABG and PCI lacked statistical power due
to a small number of participants in the PCI group (Sup-
plemental Table 4, Supplemental Digital Content 1, http://
links.lww.com/WAD/A158).
In meta-analyses, we pooled our findings with results
from the Cache County Study14 investigating the risk of all-
TABLE 2. Baseline Characteristics of CHS Participants by History of Coronary Artery Bypass Graft Surgery
Characteristics
All
(N=3155)
CABG History
(N=161)
No CABG History
(N=2994) P*
Age [mean (SD)] (y) 74.5 (4.9) 74.9 (4.2) 74.5 (4.9) 0.32
Female [n (%)] 1840 (58.3) 38 (23.6) 1802 (60.2) <0.001
White [n (%)] 2676 (84.8) 147 (91.3) 2529 (84.5) 0.02
Education [n (%)]
Did not finish high school 752 (23.8) 27 (16.8) 725 (24.2)
Finished high school/some college/vocational 1649 (52.3) 91 (56.5) 1558 (52.0) 0.10
College/professional 754 (23.9) 43 (26.7) 711 (23.8)
Cardiovascular disease [n (%)] 2317 (73.4) 161 (100) 2156 (72.0) <0.001
Hypertension [n (%)]
Normotensive 1116 (35.4) 35 (21.7) 1081 (36.1)
Treated 1516 (48.1) 109 (67.7) 1407 (47.0) <0.001
Untreated 523 (16.6) 17 (10.6) 506 (16.9)
Diabetes [n (%)] 452 (14.3) 40 (24.8) 412 (13.8) <0.001
BMI (N=3128) [mean (SD)] 26.6 (4.5) 26.5 (3.9) 26.6 (4.5) 0.61
Depressive symptoms (N=3154) [n (%)] 732 (23.2) 33 (20.5) 699 (23.4) 0.40
Current smoker (N=3090) [n (%)] 284 (9.2) 5 (3.1) 279 (9.5) 0.01
Alcohol use (N=3151) [n (%)]
Nondrinkers 1647 (52.3) 76 (47.2) 1571 (52.5)
Moderate drinkers 1154 (36.6) 68 (42.2) 1086 (36.3) 0.31
Heavy drinkers 350 (11.1) 17 (10.6) 333 (11.1)
Physical activity (N=3133) [median (IQR)] 24 (5-60) 24 (8-84) 24 (5-60) 0.02
APOE E4 alleles (N=2898) [n (%)] 700 (24.2) 28 (18.9) 672 (24.4) 0.13
Years of follow-up [median (IQR)] 6.0 (4.7-6.5) 5.9 (3.3-6.3) 6.0 (4.8-6.5) 0.03
Mild cognitive impairment [n (%)] 537 (17.0) 19 (11.8) 518 (17.3) 0.07
*P-value for a Student t test for normally distributed continuous variables, a Wilcoxon rank-sum test for skewed continuous variables and a Pearson w2 test
for categorical variables
APOE indicates apolipoprotein E; BMI, body mass index; CABG, coronary artery bypass graft surgery; CHS, Cardiovascular Health Study; IQR;
interquartile range.
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cause dementia, AD, and VaD in those with history of
CABG compared with those with no history of CABG. We
also included 2 further cohort studies16,17 comparing the
risk of all-cause dementia and AD in those with CABG to
those with PCI.
Pooled results indicated that history of CABG almost
doubled the risk of all-cause dementia compared with no
history of CABG (HR=1.96; 95% CI, 1.42-2.69;
P<0.001). History of CABG also increased the risk of
AD, though the association was slightly weaker (HR=
1.71; 95% CI, 1.04-2.79; P=0.03). Pooled results for VaD
remained statistically underpowered, and the relationship
between history of CABG and VaD remains unclear due to
wide CIs (HR=2.20; 95% CI, 0.78-6.19; P=0.24; see
Supplemental Figure 3, Supplemental Digital Content 1,
http://links.lww.com/WAD/A158).
When we pooled our findings with studies comparing
CABG to PCI, the pooled result indicated an increased risk
of all-cause dementia in those undergoing CABG (HR=
1.47; 95% CI, 1.01-2.14; P=0.05). The pooled estimate for
AD was in the same direction though not statistically sig-
nificant (HR=1.51; 95% CI, 0.89-2.55; P=0.12; see
Supplemental Figure 4, Supplemental Digital Content 1,
http://links.lww.com/WAD/A158).
DISCUSSION
The risk of all-cause dementia in those with CABG
history was approximately doubled in our analysis of the
CHS and in our meta-analysis incorporating additional
results from the Cache County Study. A similar though
slightly weaker association with AD was observed in both the
CHS and pooled results. The relationship between CABG
and VaD remained unclear even in the pooled analysis due to
a lack of statistical power. A significant association between
CABG and mixed dementia was observed in the CHS,
something that has not been investigated in previous studies.
Pooled results of studies comparing CABG to PCI suggested
an increased risk of all-cause dementia in those with CABG.
Our results add to the debate on whether CABG
increases or decreases long-term dementia risk by indicating
that a history of CABG increases the risk of all-cause
dementia, AD, and mixed dementia in older adults. This
can be contrasted with the results of a recent meta-analysis
of short-term studies suggesting that initial cognitive defi-
cits following CABG resolved within 3 months, and cog-
nition was stable or improved at 6 to 12 months.8 The fully
adjusted association between history of CABG and risk of
VaD from our analysis of the CHS is smaller (HR=1.42;
95% CI, 0.56-3.65) than that observed in a previous anal-
ysis using the CHS data (HR=2.6; 95% CI, 1.7-4.1).18
This difference is due to methodological differences
including a basic adjustment strategy (age, sex, and eth-
nicity) and the exclusion of prevalent MCI at baseline in the
previous CHS analysis.18 A case-control study15 identified
in our systematic review did not find a significant associa-
tion between CABG and odds of all-cause dementia and
AD but was excluded from our meta-analyses due to sub-
stantial differences in design as it was a retrospective
medical records study. This discrepancy may be explained
by a different study design and use of medical records to
ascertain dementia status. The significant pooled estimate
for the association between history of CABG and AD
compared with no history of CABG may reflect mixed
pathology, as many AD patients are likely to have vascular
pathology that contributes to their dementia status.29 Our
meta-analytic results suggest the significant association
between history of CABG and dementia risk is unlikely to
be driven by the underlying CAD as PCI may be associated
with lower dementia risk compared with CABG. One study
investigated dementia risk in those with a history of CABG
compared with those receiving medical management for
CAD and found no significant association, though this was
limited by the use of medical records for the primary out-
come.16 Further well-designed studies are needed to com-
pare CABG with alternative treatment strategies for CAD.
A large randomized controlled trial with long-term follow-
up could provide definitive evidence on the causal effect of
CABG but random assignment to CAD treatment may not
be ethical given potential differences in mortality linked to
type of CAD treatment.30,31 However, further observa-
tional studies could also be useful, for example, patients
receiving CABG and PCI could be propensity score
matched according to their baseline characteristics and
CAD severity.
A number of mechanisms have been identified that
may explain the association between CABG and dementia.4
A recent meta-analysis of randomized controlled trials
TABLE 3. Cox Proportional Hazards Regression Models of Incident All-cause Dementia, Alzheimer Disease, Vascular Dementia, and
Mixed Dementia by History of CABG, Where Participants Without a History of CABG Served as the Reference Group
Dementia
Status
No.
Participants
No. Dementia
Cases in Those
With CABG
History/Total
CABG History
No. Dementia
Cases in Those
Without CABG
History/Total No
CABG History
Model A
(HR)*
Model A
(95% CI)* P
Model B
(HR)w
Model B
(95% CI)w P
All-cause
dementia
3155 37/161 402/2994 2.07 1.47-2.92 <0.001 1.93 1.36-2.74 <0.001
Alzheimer
disease
2937 14/138 211/2799 1.70 0.98-2.94 0.06 1.71 0.98-2.98 0.06
Vascular
dementia
2763 5/129 51/2634 1.96 0.77-5.00 0.16 1.42 0.56-3.65 0.46
Mixed
dementia
2848 15/139 123/2709 3.08 1.77-5.35 <0.001 2.73 1.55-4.80 <0.001
*Adjusted for age, sex, ethnicity, and education.
wAdjusted for model A and cardiovascular disease, hypertension, and diabetes.
CABG indicates coronary artery bypass graft surgery; CI, confidence interval; HR, hazard ratio.
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demonstrated that those who received CABG rather than
PCI had significantly higher odds of stroke after a median
follow-up period of 12 months (OR=1.69; 95% CI, 1.07-
2.67).32 Stroke is an established dementia risk factor33 and
may therefore mediate the association between CABG and
dementia risk. Hypoperfusion during surgery affects the
washout of microemboli and is linked to brain ischemia and
infarction.34 CABG markedly increases cytokine levels as
part of the systemic inflammatory response,35 which may in
turn increase the risk of dementia.36 Given that our results
suggest the increased dementia risk associated with CABG
takes >1 year to become apparent, it is possible that these
mechanisms reduce brain reserve and increase vulnerability
to dementia by accelerating cognitive decline. Moreover,
CABG is performed under general anesthesia, whereas PCI
often requires no sedation or conscious sedation.37 Results
of studies investigating the association between general
anesthesia and dementia risk are mixed. A systematic
review and meta-analysis of 15 case-control studies sug-
gested no significant association with odds of AD,38
whereas 2 recent large case-control studies from Taiwan
reported increased dementia risk.39,40
The strengths of our study include the incorporation
of a systematic review, analysis of data from a large pro-
spective population-based cohort with long follow-up and
adjudicated dementia status, and meta-analyses conducted
to obtain more robust estimates of the association between
CABG and risk of all-cause dementia and its subtypes.
Restricting the sample to those with CVD or CAD did not
alter the pattern of results suggesting that the observed
associations are not driven by differences in dementia risk
associated with CVD or CAD itself. Likewise, the associ-
ations between dementia risk and CVD (HR=1.3; 95%
CI, 1.0-1.6), myocardial infarction (HR=1.3; 95% CI, 1.0-
1.9), or angina pectoris (HR=1.3, 95% CI, 1.0-1.7)
observed previously in the CHS41 were much smaller than
the association observed with CABG. A Finnish
population-based study with a follow-up of over 25 years
also did not find an association between midlife or late-life
CAD and risk of all-cause dementia or AD.42 However, we
cannot exclude the possibility that the increased dementia
risk associated with CABG may be due to the severity of
CVD or CAD and our results do not prove a causal rela-
tionship. It is unlikely that dementia causes CAD, but
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FIGURE 1. Kaplan-Meier curves for unadjusted rates of all-cause dementia, Alzheimer disease, vascular dementia, and mixed dementia
by history of CABG in the Cardiovascular Health Study. CABG indicates coronary artery bypass graft surgery; CI, confidence interval.
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reverse causation is possible if dementia influences treat-
ment for CAD and the likelihood of receiving CABG. That
said, the exclusion of participants with prevalent dementia
or incident dementia occurring within a year of baseline
and the long follow-up in our study makes reverse causa-
tion less likely. We adjusted our analyses for a wide range
of potential confounders but the possibility of residual
confounding remains. The CHS included only white and
African American participants, dementia subtypes were not
pathologically confirmed, and the exact timing of CABG is
unknown for self-reported cases precluding adjustment for
preoperative cognitive function. Statistical power was also
limited in several analyses, particularly for VaD and the
comparisons between CABG and PCI.
In conclusion, our findings suggest that history of CABG
is associated with the long-term risk of all-cause dementia,
AD, and mixed dementia. Patients receiving CABG may have
an increased risk of dementia compared with those receiving
PCI. Much uncertainty on this topic remains and as a result
caution is warranted. Further studies are needed to investigate
potential causal mechanisms or whether the association reflects
CAD severity. The relationship between CABG and VaD
needs addressing, particularly given the plausible vascular
mechanisms identified. The impact of CABG in midlife and
late-life should be investigated to establish whether there is a
critical period, or whether CABG at any time increases
dementia risk. If future research confirms a causal association
between CABG and dementia risk then this would have
important clinical implications. For example, alternative CAD
procedures such as PCI could be considered in appropriate
patients to reduce their long-term dementia risk.
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